Nirogacestat

Chemical formula: C₂₇H₄₁F₂N₅O  Molecular mass: 489.328 g/mol  PubChem compound: 46224413

Interactions

Nirogacestat interacts in the following cases:

CYP2C8, CYP2C9, CYP2C19, and CYP2B6 substrates

In vitro studies showed that nirogacestat may induce CYP2C8, CYP2C9, CYP2C19, and CYP2B6 and thus there is a risk that nirogacestat can cause decreased exposure of substrates of these enzymes. When substrates of CYP2C8, CYP2C9, CYP2C19, and CYP2B6 are administered with nirogacestat, evaluation for reduced efficacy of the substrate should be performed and dose adjustment of the substrate may be required to maintain optimal plasma concentrations.

CYP3A4 substrates that have narrow therapeutic indices

A drug‑drug interaction study in healthy volunteers investigating the effects of multiple doses of nirogacestat at a dose of 95 mg once daily on the exposure of midazolam, a sensitive CYP3A4 substrate, resulted in a 1.3‑fold increase in midazolam Cmax and a 1.6‑fold increase in midazolam AUC. The effect of the clinical dose of nirogacestat (150 mg twice daily) on midazolam exposure has not been studied and may be different. Nirogacestat should not be used with concomitant administration of CYP3A4 substrates that have narrow therapeutic indices (e.g., cyclosporine, tacrolimus, digitoxin, warfarin, carbamazepine).

Moderate and strong CYP3A4 inhibitors

In a clinical study, co‑administration of itraconazole (a strong CYP3A4 inhibitor and P‑gp inhibitor) increased nirogacestat Cmax by 2.5‑fold and AUC by 8.2‑fold. Co‑administration with moderate CYP3A4 inhibitors is also expected to result in clinically relevant increases in exposure.

Concomitant use with strong inhibitors of CYP3A4 (e.g., clarithromycin, oral ketoconazole, itraconazole) and moderate inhibitors of CYP3A4 (e.g., erythromycin and fluconazole) should therefore be avoided.

Alternative concomitant medicinal products with no or minimal CYP3A4 inhibition should be considered. If therapeutic alternatives are not available, nirogacestat should be immediately interrupted for the period of time in which a strong or moderate CYP3A4 inhibitor is given.

Patients should avoid consuming grapefruit and grapefruit juice when taking nirogacestat since they include inhibitors of CYP3A4.

Moderate and strong CYP3A4 inducers

The effects of CYP3A4 inducers on nirogacestat exposure have not been evaluated in a clinical study. Moderate and strong inducers are expected to result in clinically relevant decreases in exposure of nirogacestat that could lead to reduced efficacy. Concomitant treatment with strong inducers of CYP3A4 (e.g., carbamazepine, phenytoin, rifampicin, phenobarbital and St. John's wort) and moderate CYP3A inducers (e.g., efavirenz and etravirine) should therefore be avoided. In patients for whom CYP3A4 inducers are indicated, alternative agents with less enzyme induction potential should be selected.

Severe renal impairment

Administration is not recommended in patients with severe renal impairment.

Severe hepatic impairment

Administration is not recommended in patients with severe hepatic impairment.

Acid reducing agents

Nirogacestat has pH‑dependent solubility, with substantially reduced solubility at pH greater than 6.0. The effects of acid reducing agents (i.e., H2‑receptor antagonists, proton pump inhibitors and antacids) on nirogacestat exposure have not been evaluated in a clinical study, however, co‑administration of these medicinal products may reduce the bioavailability of nirogacestat. Concomitant use of nirogacestat with proton pump inhibitors and H2 blockers is not recommended. However, if concomitant use with acid reducing agents cannot be avoided, nirogacestat can be staggered with antacids by administering nirogacestat 2 hours before or 2 hours after antacid use.

Fertility

Fertility studies were not conducted in humans. The effect of nirogacestat on fertility in humans is not known. Based on findings from animal studies, male and female fertility may be impaired.

Pregnancy

Based on findings from animal studies and its mechanism of action, nirogacestat may cause foetal harm when administered to a pregnant woman. Nirogacestat is contraindicated in pregnant women. Women of childbearing potential must have a negative pregnancy test prior to initiating nirogacestat treatment. Pregnancy testing during treatment with nirogacestat should be considered for women of childbearing potential experiencing amenorrhoea. Patients should be advised of the potential risk to a foetus. If a patient becomes pregnant while taking nirogacestat, treatment must be discontinued. A spontaneous abortion was reported by a woman in the DeFi study who conceived while receiving nirogacestat.

Nursing mothers

There are no data regarding the presence of nirogacestat or its metabolites in either human or animal milk or its effects on a breastfed child or on milk production. Because of the potential for serious adverse reactions in a breastfed child, women must not breastfeed during treatment with nirogacestat and for 1 week after the last dose of nirogacestat.

Carcinogenesis, mutagenesis and fertility

Women of childbearing potential/Contraception in males and females

Women of childbearing potential and men with female partners of childbearing potential should be advised to avoid pregnancy while on nirogacestat.

Women of childbearing potential must use highly effective contraceptive methods during treatment with nirogacestat and for 1 week after the last dose of nirogacestat. It is unknown whether nirogacestat reduces the effectiveness of systemically acting hormonal contraceptives. Patients should be advised to use at least one highly effective method of contraception (such as an intrauterine device) or two complementary forms of contraception including a barrier method during treatment with nirogacestat and for 1 week after the last dose of nirogacestat. Women of childbearing potential should be advised to inform their healthcare provider immediately of a known or suspected pregnancy, and they must stop taking nirogacestat if they become pregnant. Women of childbearing potential should not donate eggs (oocytes) during treatment with nirogacestat and for 1 week after the last dose of nirogacestat.

Male patients with female partners of childbearing potential must use highly effective contraceptive methods during treatment with nirogacestat and for 1 week after the last dose of nirogacestat. Male patients should not donate sperm during treatment with nirogacestat and for 1 week after the last dose of nirogacestat.

Fertility

Fertility studies were not conducted in humans. The effect of nirogacestat on fertility in humans is not known. Based on findings from animal studies, male and female fertility may be impaired.

Effects on ability to drive and use machines

Nirogacestat has no or negligible influence on the ability to drive and use machines. Since fatigue and dizziness may occur in patients taking nirogacestat, caution should be observed by patients who experience those adverse reactions when driving or operating machinery.

Adverse reactions


Summary of the safety profile

The most common adverse reactions are: diarrhoea (85%), rash (65%), ovarian toxicity in women of childbearing potential (60%), nausea (59%), fatigue (50%), hypophosphataemia (50%), headache (40%), and stomatitis (40%).

The most frequently reported serious adverse reaction was ovarian toxicity (premature menopause, 3%). The most common severe adverse reactions were diarrhoea (16%) and hypophosphataemia (13%).

Permanent discontinuation of nirogacestat due to an adverse event occurred in 19% of patients. The most common adverse reactions leading to discontinuation were diarrhoea (5%), ovarian toxicity (5%), and increased ALT (3%).

The frequency of dose interruption of nirogacestat due to adverse reactions was 59%. The most common adverse reactions leading to dose interruption were diarrhoea (11%), rash maculo-papular (10%), hypophosphatemia (6%) and nausea (5%). The frequency of dose reduction of nirogacestat due to adverse reactions was 44%. The most common adverse reactions leading to dose reduction were diarrhoea (9%), rash maculo-papular (6%), stomatitis (3%), and hypophosphatemia (3%).

Tabulated list of adverse reactions

Unless otherwise stated, the frequencies of adverse reactions are based on all-cause adverse event frequencies identified in 88 patients exposed to nirogacestat 150 mg twice daily during a median duration of 21.5 months in clinical studies.

The adverse reactions are ranked under heading of frequency using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1 000 to <1/100), rare (≥1/10 000 to <1/1 000), very rare (<1/10 000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Adverse reactions reported:

System organ classAdverse reactionAll gradesGrades 3-4
Gastrointestinal
disorders
DiarrhoeaVery commonVery common
NauseaVery commonCommon
StomatitisaVery commonCommon
Dry mouthVery common--
Skin and subcutaneous
disorders
RashbVery commonCommon
AlopeciaVery common--
FolliculitisVery commonCommon
HidradenitisCommonCommon
Dry skinVery common--
PruritisVery common--
Neoplasms benign,
malignant and
unspecified
Basal cell carcinomaCommon--
Squamous cellc
carcinoma
Common--
Metabolism and
nutrition disorders
HypophosphataemiaVery commonVery common
HypokalaemiaVery commonCommon
Nervous system
disorders
HeadacheVery common--
DizzinessVery common--
InvestigationProteinuriaVery common--
GlycosuriaVery common--
Blood and lymphatic
system disorders
EosinophiliaVery common--
Renal and urinary
disorders
Renal tubular
disorder
Common--
Injury, poisoning and
procedural
complications
Bone fracturedCommon--
Hepatobiliary disordersALT increasedVery commonCommon
AST increasedVery commonCommon
Reproductive system and
breast disorders
Ovarian toxicityeVery common--
Respiratory, thoracic
and mediastinal
disorders
CoughVery common--
Upper respiratory
tract infectionf
Very common--
DyspnoeaVery common--
EpistaxisVery common--
General disorders and
administration site
conditions
FatigueVery commonCommon
Influenza-like illnessVery common--

a Stomatitis includes stomatitis, mouth ulceration, oral pain, and oropharyngeal pain.
b Rash includes rash maculo-papular, dermatitis acneiform, rash, rash erythematous, rash pruritic, and rash papular.
c Squamous cell carcinoma included squamous cell carcinoma of skin and squamous cell carcinoma.
d Bone fracture includes fracture, foot fracture, hand fracture, radius fracture, hip fracture and rib fracture.
e Ovarian toxicity includes ovarian failure, premature menopause, amenorrhoea, oligomenorrhoea, menstruation irregular, dysmenorrhoea, heavy menstrual bleeding, vulvovaginal dryness, hot flush, decreased anti-Müllerian hormone (AMH) and increased follicle-stimulating hormone (FSH).
f Upper respiratory tract infection (URTI) includes URTI, viral URTI, acute sinusitis, and sinusitis.
-- Represents no cases were reported.

Description of selected adverse reactions

The data described below reflect results of the randomised, double-blind, Phase 3 DeFi study in patients with desmoid tumours treated with 150 mg BID nirogacestat (N=69) or placebo (N=72) twice daily.

Diarrhoea

In the double-blind phase of the DeFi study, diarrhoea was reported in 84% of patients receiving nirogacestat compared to 35% in patients receiving placebo. Grade 3 events occurred in 16% and 1% of patients, respectively. Grade ≤ 2 diarrhoea resolved in 74% of patients who continued on nirogacestat treatment. The median time to first onset of diarrhoea in patients receiving nirogacestat was 9 days (range 2 to 234 days). Diarrhoea led to dose reduction in 10% of patients and treatment discontinuation in 7% receiving nirogacestat.

Skin and subcutaneous tissue disorders

In the double‑blind phase of the DeFi study, dermatologic reactions were reported at a higher incidence in patients receiving nirogacestat than in those receiving placebo; they included maculo‑papular rash (32% vs 6%), hidradenitis (9% vs 0), and folliculitis (13% vs 0). The median time to rash events was 22 days (range 2 to 603 days). Skin and subcutaneous disorders led to dose reduction in 9% of patients receiving nirogacestat, including maculo‑papular rash in 4% and hidradenitis in 3%. Maculo‑papular rash led to treatment discontinuation in 1%.

Ovarian toxicity

In the double‑blind phase of the DeFi study, 75% of women of childbearing potential receiving nirogacestat reported ovarian toxicity (defined as ovarian failure, premature menopause, amenorrhea, oligomenorrhea, and menopause) compared to no patients receiving placebo. There were three serious adverse reactions of ovarian toxicity, all premature menopause, representing 11% of all participants reporting ovarian toxicity. The median time to first onset of ovarian toxicity was 8.9 weeks (range 1 day to 54 weeks), and the overall median duration was 18.9 weeks (range 11 days to 215 weeks). Ovarian toxicity has been reported to resolve in 79% of women of childbearing potential during treatment. Follow up information is available for all but two out of 27 patients; after stopping treatment, ovarian toxicity was reported to resolve in all women of childbearing potential for whom data are available. The median time to resolution after discontinuing nirogacestat was 10.9 weeks (range 4 to 18 weeks). Effects of nirogacestat on fertility are unknown. An exposure-response relationship was identified between nirogacestat and serum follicular stimulating hormone (FSH) levels, with FSH increasing linearly with increasing serum concentrations of nirogacestat.

Electrolyte abnormalities

Electrolyte abnormalities were reported in patients receiving nirogacestat in the double‑blind phase of the DeFi study, including hypophosphataemia (43%) and hypokalaemia (12%), compared to 7% and 1%, respectively, in patients receiving placebo. Median time to first onset of hypophosphataemia and hypokalaemia was 15 days (range 1 to 833 days) and 15 days (range 1 to 57 days), respectively. Grade 3 events of hypophosphataemia and hypokalaemia occurred in 3% of patients receiving nirogacestat compared to no patients receiving placebo. Hypophosphataemia and hypokalaemia led to dose reduction in 4% and 1% of patients receiving nirogacestat, respectively. Hypophosphataemia led to dose discontinuation in 1% of patients receiving nirogacestat.

Hepatic abnormalities

ALT and AST elevations were reported in 19% and 17%, respectively, of patients receiving nirogacestat in the double‑blind phase of the DeFi study compared to 8% and 11%, respectively, in patients receiving placebo. Median time to first onset of ALT and AST elevations was 22 days (ALT range 8 to 924 days; AST range 1 to 1023 days). Grade 3 ALT and AST elevations (>5 x ULN) occurred in 3% of patients treated with nirogacestat compared to 1% in the placebo arm. ALT and AST elevations each led to dose reduction in 1% of patients receiving nirogacestat. ALT and AST elevations led to dose discontinuation in 4% and 3% of patients receiving nirogacestat, respectively.

Non-melanoma skin cancers

Non-melanoma skin cancers were reported at a higher incidence in patients receiving nirogacestat than in those receiving placebo in the double‑blind phase of the DeFi study, including squamous cell carcinoma (3% vs 0) and basal cell carcinoma (1% vs 0), with one patient reporting both types of non‑melanoma skin cancer. An additional two cases of non‑melanoma skin cancer were reported outside of the double‑blind phase of the DeFi study.

Proximal renal tubule effect

Glycosuria and proteinuria were observed in 52% and 46%, respectively, of patients receiving nirogacestat in the double‑blind phase of the DeFi study, compared with 1% and 39%, respectively, in patients receiving placebo. Median time to onset of glycosuria and proteinuria was 85 days (range 55 to 600 days) and 72 days (range 38 to 937 days), respectively. One patient in the DeFi study reported renal tubular disorder with increased urinary excretion of uric acid, glucose and phosphate, but no excess excretion of low molecular weight proteins (beta2‑microglobulin) or any change in renal function. The event was managed with dose reduction.

Bone fracture

In the double‑blind phase of the DeFi study, bone fractures were reported in 6% of patients receiving nirogacestat compared with no patients receiving placebo. All reports of bone fracture were non‑serious and Grade 1 or 2. The median time to first onset of bone fracture events in patients receiving nirogacestat was 125 days (range 1 to 739 days). Bone fracture events did not lead to dose reduction or treatment discontinuation in any patient receiving nirogacestat.

Paediatric population

Epiphyseal disorder, manifesting as a widening of the epiphyseal growth plate, was reported in 4 of 26 (15%) paediatric patients with open growth plates treated with nirogacestat outside of the DeFi study. The events included epiphysiolysis, hip fracture, epiphyseal disorder, and osteonecrosis. All 4 paediatric patients were between the ages of 11 and 12 years.

Cross-check medications

Review your medication to ensure that there are no potentially harmful drug interactions or contraindications.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈